Ravulizumab: a complementary option for PNH

摘要

In this issue of Blood, Lee et al(1) and Kulasekararaj et al(2) report the results of 2 phase 3, open-label, multicenter trials evaluating the efficacy and safety of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria (PNH).